News & Media

September 25, 2023

WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC® ON THE LEAD COMPOUND, TTX (HALNEURON®)

Read more
September 12, 2023

WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION ON HALNEURON® AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC®

Read more
August 22, 2023

News Brief: WEX Pharmaceuticals Inc. Announces Addition Of Intellectual Property For Its Novel Development And Use Of Tetrodotoxin (TTX) To Relieve Pain

Read more
March 21, 2023

News Brief: WEX Pharmaceuticals Inc. Enrolls In Korea As Part Of The Multinational Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain

Read more
February 8, 2023

News Brief: WEX Pharmaceuticals Inc. Announces Management Changes

Read more
January 3, 2023

News Brief: WEX Pharmaceuticals Inc. Enrolls The First Patient In The Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain

Read more
November 30, 2022

News Brief: Wex Pharmaceuticals Inc. Announces Authorization For The Conduct Of A Chemotherapy-induced Neuropathic Pain Clinical Trial In China, Singapore, Taiwan, Korea, Usa, And Canada

Read more
September 22, 2022

News Brief: Wex Pharmaceuticals Inc. Announces A Scientific Poster Presentation At The IASP World Congress On Pain On Its Lead Compound, Halneuron®

Read more
1 2